Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270408 | 0.89 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209414 | 0.86 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209311 | 0.83 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209262 | 0.81 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209437 | 0.80 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209399 | 0.80 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL30063084 | 0.78 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25226194 | 0.77 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23233971 | 0.75 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25223633 | 0.74 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| CN-119930610-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930611-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115298177-B | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| CN-115298177-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | JAK2 2076/4885JAK1 1378/4885TYK2 2563/4885 |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.